Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Agro Chemicals | Small Cap
Health Score : 4.06Astec Lifesciences, operating in the Chemical & Petrochemicals sector, shows a mixed financial performance. The company demonstrates strengths in solvency, driven by a manageable debt-to-equity ratio and reasonable interest coverage. However, it faces challenges in efficiency, particularly in inventory and receivables management. Growth metrics reveal a decline in revenue and operating profit, alongside a concerning trend in earnings per share. While asset growth remains strong, profitability is under pressure due to shrinking margins and returns. The financial ratios show strengths in book value per share and capital expenditure management, but weaknesses in adjusted earnings and dividend payouts. Overall, Astec Lifesciences exhibits financial resilience but needs to address declining profitability and efficiency to ensure sustainable growth.
Health Score : 4.06Astec Lifesciences, operating in the Chemical & Petrochemicals sector, shows a mixed financial performance. The company demonstrates strengths in solvency, driven by a manageable debt-to-equity ratio and reasonable interest coverage. However, it faces challenges in efficiency, particularly in inventory and receivables management. Growth metrics reveal a decline in revenue and operating profit, alongside a concerning trend in earnings per share. While asset growth remains strong, profitability is under pressure due to shrinking margins and returns. The financial ratios show strengths in book value per share and capital expenditure management, but weaknesses in adjusted earnings and dividend payouts. Overall, Astec Lifesciences exhibits financial resilience but needs to address declining profitability and efficiency to ensure sustainable growth.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-1.36
Industry Median
26.62
Small Cap Median
24.65
P/E RATIO
-1.15
P/B RATIO
0.37
Industry Median
3.32
Small Cap Median
3.13
P/S RATIO
N/A
Industry Median
1.80
Small Cap Median
1.46
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-2.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹69.06 as on Feb 20, 2026.
Growth Score : 2.80The growth ratios present a mixed picture. While asset growth is strong, declines in revenue, operating profit, and earnings per share raise concerns about the company's ability to sustain growth. The company needs to address the factors contributing to these declines to ensure future growth prospects. Diversifying revenue streams and exploring new market opportunities could help revitalize growth.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 21.98 | -7.24 | -27.07 | -16.81 | 17.59 |
| Operating Profit Growth Rate | 37.5 | -50 | -107.79 | 1000 | -92.42 |
| Earnings Per Share (EPS) Growth | 38.15 | -71.56 | -283.61 | 187.16 | -39.63 |
| Asset Growth Rate | 32.3 | 9.14 | -0.41 | -9.64 | 6.92 |
| Net Income Growth Rate | 38.46 | -71.11 | -280.77 | 187.23 | -40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Astec Lifesciences Ltd | 4.06 | -1.15 | Neutral | -5.00 | -36.35 | -81.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤27th Apr 26
Audited Standalone Financial Results for the Quarter and Full Year Ending March 31, 2026
UNDEFINED SENTIMENT
Astec Lifesciences Ltd. is a leading Indian manufacturer of active ingredients, intermediates, and speciality chemicals, primarily serving the agrochemical and pharmaceutical sectors. The company specializes in Contract Manufacturing and Research Services (CRAMS), offering integrated solutions to global clients and positioning itself as a key player in value-added chemical production.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Astec Lifesciences Ltd's P/E ratio (TTM) is -1.36, compared to the industry median of 26.62 and large cap median of 24.65.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Astec Lifesciences Ltd's P/B ratio is 0.37, compared to the industry median of 3.32 and large cap median of 3.13.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Astec Lifesciences Ltd's P/S ratio is N/A, compared to the industry median of 1.80 and large cap median of 1.46.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Astec Lifesciences Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Astec Lifesciences Ltd's EV/EBITDA ratio is -2.57.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Astec Lifesciences Ltd's ROE is -20.77%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Astec Lifesciences Ltd's ROA is -0.53%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Astec Lifesciences Ltd's ROCE is -5%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Astec Lifesciences Ltd's operating margin is -1.12%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Astec Lifesciences Ltd's net margin is -18.08%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Astec Lifesciences Ltd's current ratio is 0.92.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Astec Lifesciences Ltd's debt-to-equity ratio is 0.12.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Astec Lifesciences Ltd's interest coverage ratio is -1.31.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Astec Lifesciences Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Astec Lifesciences Ltd's EPS is -39.63.
(Source line: "Ratios as of 20 Feb 2026, based on last traded price of ₹69.06. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Astec Lifesciences was incorporated in 1994 as Astec Chemicals Private Limited. It transitioned to a public limited company in 2000. A significant milestone occurred in 2007 when Godrej Agrovet Ltd (GAVL) acquired a controlling stake, leading to a strengthened focus on contract manufacturing and the production of active ingredients for agrochemicals. Over the years, Astec has expanded its product portfolio and global client base, establishing itself as a key player in the specialty chemicals and CRAMS space.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Agrochemicals (Active Ingredients & Intermediates) | 75-80% | Operating Profit |
| Pharmaceutical Intermediates & Specialty Chemicals (incl. CRAMS) | 20-25% | Operating Profit |
Mr. Anklesaria Varun Ritesh: Whole-time Director & CEO. He holds a degree in Chemical Engineering and has significant experience in the chemical and pharmaceutical industries, driving the company's growth and operational excellence.
No major subsidiaries reported.
No major recent corporate actions on record.
References
The Astec Lifesciences Ltd share price today is ₹69.06 on NSE (ASTEC), as of 18 Aug 2026.
As of 20 Feb 2026, Astec Lifesciences Ltd share price is ₹69.06, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Astec Lifesciences Ltd's market cap is ₹154 crore (Small Cap).
Astec Lifesciences Ltd's current P/E ratio is -1.36, compared to the Chemical & Petrochemicals sector average of 29.
Astec Lifesciences Ltd's current P/B ratio is 0.37.
Astec Lifesciences Ltd's current dividend yield is N/A. Last dividend of ₹1.50 per share was declared on 24-May-2023.
Astec Lifesciences Ltd's EPS (TTM) is ₹-39.63.
Astec Lifesciences Ltd. is a leading Indian manufacturer of active ingredients, intermediates, and speciality chemicals, primarily serving the agrochemical and pharmaceutical sectors. The company specializes in Contract Manufacturing and Research Services (CRAMS), offering integrated solutions to global clients and positioning itself as a key player in value-added chemical production.
Astec Lifesciences Ltd is promoted by Godrej Agrovet Limited, holding 71.97% as of 20 Feb 2026.
Astec Lifesciences Ltd is listed on NSE (ASTEC) and BSE (533138). Its next quarterly results are expected on August 2024.
Cash Earnings Per Share (Cash EPS)
Gross Profit Margin